Rapport Therapeutics, Inc. 8-K

What Happened Rapport Therapeutics, Inc. filed a prospectus supplement on January 7, 2026 to its effective Form S-3 registration statement to register the offer and sale of up to $110,000,000 aggregate price of its common stock. The shares are to be offered from time to time through Leerink Partners LLC and Cantor Fitzgerald & Co., acting as sales agents under the Sales Agreement dated July 1, 2025. The company disclosed that, as of the filing date, no sales have been made under the Sales Agreement. The legal opinion of Goodwin Procter LLP relating to the offering is filed as an exhibit.

Key Details

• Aggregate offering size: up to $110,000,000 of common stock.
• Sales agents: Leerink Partners LLC and Cantor Fitzgerald & Co.; sales pursuant to the Sales Agreement dated July 1, 2025.
• Filing date: January 7, 2026; no sales under the agreement as of that date.
• Legal opinion of Goodwin Procter LLP included as Exhibit 5.1 to the 8-K.

Why It Matters This filing registers the company’s ability to raise capital by selling common stock over time through designated sales agents (an ATM-style arrangement). For investors, that means Rapport can access equity capital flexibly and quickly, which can support operations or development programs but would dilute existing shareholders if and when shares are sold. Monitor future SEC filings and company announcements for actual sales, amounts raised, and any use of proceeds.